Our Medicines Australia Horizon Scanning Forum presentation highlighted the journey of AI-enabled IVD from Parkinson’s prognosis to broader neurological applications. As advancements continue, we see these tools embracing conditions like Alzheimer’s, reshaping diagnosis and treatment landscapes.
Oona Reardon delved into the regulatory and HTA impacts of this new health technology to the Australian healthcare system. AI-enabled IVD stands to cut through the high costs associated with neurological disorders. By reducing misdiagnosis and inappropriate treatments, this technology will result in substantial savings for the healthcare system.
The current lack of disease-modifying therapies for Parkinson’s and Alzheimer’s adds complexity to reimbursement for IVDs. Early collaboration across the healthcare spectrum is crucial. By aligning efforts now, we can ensure AI-enabled IVD tools swiftly integrate into clinical practice, marking a new era in neurodegenerative care.
